Liquidia Corporation (LQDA) fair value analysis
Nasdaq · Updated 2026-10-19
LQDA price how computed
Valuation status
Awaiting full valuationLQDA's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once LQDA's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $34.35
- Sector
- Healthcare
- 12-month range
- $22.38–$91.03
- Market cap
- $3.07B
- From 52-week high
- -62.3%
- Shares outstanding
- 89.5M
- Rank in Healthcare by quality score
- #47 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Liquidia Corporation is a biopharmaceutical company that develops and commercializes medicines using its proprietary PRINT technology platform for targeted drug delivery. The company is based in Research Triangle Park, North Carolina and operates in the healthcare sector.
LQDA currently ranks #47 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $3.07B
- P/E (trailing)
- 245x
- Revenue (TTM)
- $451M
- Net margin
- 30.7%
- EPS (TTM)
- $0.14
- Gross margin
- 93.3%
- Debt / equity
- 0.66
- Revenue growth (3-yr avg)
- 1522.6%
- Shares outstanding
- 89.5M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 31 · neutral
- 50-day average
- $60.52
- 200-day average
- $53.92
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-02
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-170.0%)
2026-03 ▲ beat (+28.4%)
2025-12 ▼ miss (-22.0%)
2025-09 ▲ beat (+88.6%)
2025-06 ▼ miss (-25.6%)
2025-03 ▼ miss (-7.1%)
2024-12 ▼ miss (-21.1%)
2024-09 ▲ beat (+2.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 2 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $54.4
- Target vs last price
- +58.4%
What our data shows for LQDA
- Shares are trading in the lower third of their 12-month price range of $22.38–$91.03.
- The 14-day relative strength index sits at a neutral 31.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- LQDA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LQDA news
TickrTrends' derived news-sentiment signal for LQDA is currently leaning positive, computed from recent coverage.
- Arquitos Capital Q2 2026 Investor Letter (seekingalpha.com, 2026-10-22)
- LQDA Upgraded by LifeSci Capital -- Price Target Announced at $59.00 (gurufocus.com, 2026-10-14)
- Liquidia Corporation (LQDA) Shares Surge 27% After Global Settlement with United Therapeutics (gurufocus.com, 2026-10-14)
More LQDA news
- Liquidia soars 27% after settlement resolves litigation (LQDA:NASDAQ) (seekingalpha.com, 2026-10-14)
- Liquidia (LQDA) Shares Surge 42% on $380.7M Settlement with United Therapeutics (gurufocus.com, 2026-10-14)
- Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH (manilatimes.net, 2026-10-13)
- Liquidia (LQDA) Shares Plunge After Patent Ruling and Analyst Downgrades (gurufocus.com, 2026-10-02)
What people are saying
Follow the LQDA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for LQDA showed a shift this week as the RSI zone moved from oversold to neutral territory. The stock's current valuation verdict remains awaiting full valuation. This change reflects a movement in momentum positioning within the healthcare sector.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for LQDA showed two notable shifts this week. The quality grade declined from A to B, while the relative strength index moved from neutral territory into oversold conditions. The stock's valuation verdict remains under review pending complete analysis.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LQDA stock undervalued?
LQDA's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is LQDA's TickrTrends verdict?
LQDA is currently marked 'Awaiting full valuation' - a verdict publishes automatically once LQDA's own trailing P/E history validates under our standards.
How does LQDA compare to other Healthcare stocks?
LQDA ranks #47 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is LQDA overbought or oversold?
LQDA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does LQDA report earnings next?
LQDA's next earnings report is scheduled for 2026-11-02, per the published earnings calendar.
Does LQDA usually beat earnings estimates?
Over its last 8 reported quarters LQDA beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LQDA?
Of 8 analysts covering LQDA, 6 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $54.4 (+58.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.